Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat

References

• Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006;6:546–58
   PubMed Web of Science ®Google Scholar
• Wood AJ, Savage DG, Antman KH. Imatinib mesylate – a new oral targeted therapy. New Engl J Med 2002;346:683–93
   PubMed Web of Science ®Google Scholar
• Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493–502
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 2002;347:472–80
   PubMed Web of Science ®Google Scholar
• Dagher R, Cohen M, Williams G, et al. Approval summary imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034–8
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640–53
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001;344:1031–7
   PubMed Web of Science ®Google Scholar
• Bolton A, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemoth Pharm 2004;53:102–6
   PubMed Web of Science ®Google Scholar
• Kajita T, Higashi Y, Imamura M, et al. Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats. J Pharm Pharmacol 2006;58:997–1000
   PubMed Web of Science ®Google Scholar
• Nassar I, Pasupati T, Judson JP, Segarra I. Reduced exposure of imatinib after coadministration with acetaminophen in mice. Indian J Pharmacol 2009;41:167--72
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou L, Dutreix C, et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Brit J Clin Pharmaco 2008;65:885–92
   PubMed Web of Science ®Google Scholar
• Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004;54:290–4
   PubMed Web of Science ®Google Scholar
• Severino G, Chillotti C, De Lisa R, et al. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 2005;39:162–4
   PubMed Web of Science ®Google Scholar
• Karonen T, Laitila J, Niemi M, et al. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol 2012;68:681–8
   PubMed Web of Science ®Google Scholar
• Malhotra B, Dickins M, Alvey C, et al. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Brit J Clin Pharmaco 2011;72:263–9
   PubMed Web of Science ®Google Scholar
• Hamberg P, Woo MM, Chen L-C, et al. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemoth Pharm 2011;68:805–13
   PubMed Web of Science ®Google Scholar
• Kummer O, Hammann F, Moser C, et al. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 2011;67:63–71
   PubMed Web of Science ®Google Scholar
• Tapaninen T, Backman JT, Kurkinen KJ, et al. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol 2011;51:359–67
   PubMed Web of Science ®Google Scholar
• Templeton I, Peng C, Thummel K, et al. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther 2010;88:499–505
   PubMed Web of Science ®Google Scholar
• Spriet I, Grootaert V, Meyfroidt G, et al. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug–drug interaction. Eur J Clin Pharmacol 2013;69:737–8
   PubMed Web of Science ®Google Scholar
• Hussaini T, Rüping MJ, Farowski F, et al. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacother: J Human Pharmacol Drug Ther 2011;31:214–25
   Web of Science ®Google Scholar
• Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion. J Clin Pharmacol 2004;44:158–62
   PubMed Web of Science ®Google Scholar
• Parrillo-Campiglia S, Ercoli MC, Umpierrez O, et al. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther 2009;31:2224–32
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879–94
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022–8
   PubMed Web of Science ®Google Scholar
• O'Brien S, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Brit J Cancer 2003;89:1855–9
   PubMed Web of Science ®Google Scholar
• Gschwind H-P, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005;33:1503–12
   PubMed Web of Science ®Google Scholar
• Soo GW, Law JH, Kan E, et al. Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice. Anticancer Drug 2010;21:695–703
   Google Scholar
• Weitschies W, Bernsdorf A, Giessmann T, et al. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharmaceut Res 2005;22:728–35
   PubMed Web of Science ®Google Scholar
• Plusquellec Y, Campistron G, Staveris S, et al. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Phar 1987;15:225–39
   Web of Science ®Google Scholar
• Wang Y, Roy A, Sun L, Lau CE. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 1999;27:855–9
   PubMed Web of Science ®Google Scholar
• Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 2003;43:211–27
   PubMed Web of Science ®Google Scholar
• Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacother: J Human Pharmacol Drug Ther 2006;26:1730–44
   Web of Science ®Google Scholar
• Zhang S, Pillai VC, Mada SR, et al. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica 2012;42:409–16
   PubMed Web of Science ®Google Scholar
• Zhong JS, Meng FY, Xu D, et al. Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients. Natl Med J China 2011;91:2120–3
   Google Scholar
• Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011;12:861–72
   PubMed Web of Science ®Google Scholar
• Miu HL, Liu ML. P-glycoprotein and pharmacokinetics. China Pharm 2002;13:49--51
   Google Scholar
• Babu PR, Babu KN, Peter PL, et al. Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. Drug Dev Ind Pharm 2013;39:873–9
   PubMed Web of Science ®Google Scholar
• Ding R, Tayrouz Y, Riedel K-D, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004;76:73–84
   PubMed Web of Science ®Google Scholar
• Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999;66:33–9
   PubMed Web of Science ®Google Scholar
• Challa VR, Babu PR, Challa SR, et al. Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Drug Dev Ind Pharm 2013;39:865–72
   PubMed Web of Science ®Google Scholar
• Perloff ES, Duan SX, Skolnik PR, et al. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005;33:764–70
   PubMed Web of Science ®Google Scholar
• Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248–60
   PubMed Web of Science ®Google Scholar
• Brüggemann RJ, Alffenaar J-WC, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48:1441–58
   PubMed Web of Science ®Google Scholar